New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
09:18 EDTVEEV, NAVB, SWHC, NLSN, THRM, USU, IMRS, CSIQ, YONG, XOMA, AVAVOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Smith & Wesson (SWHC), up 10%... AeroVironment (AVAV), up 7%... Gentherm (THRM), up 4%... Veeva (VEEV), up 5%. ALSO HIGHER: Dara (DARA), up 19% after signing agreement with WellCare (WCG) for Soltamox formulary status... Navidea (NAVB), up 3.7% after announcing FDA accepts sNDA to further expand Lymphoseek labeling. DOWN AFTER EARNINGS: Canadian Solar (CSIQ), down 5.4%... IMRIS (IMRS), down 3%. ALSO LOWER: XOMA (XOMA), down 21% after Phase II trial failure of gevokizumab in Erosive Osteoarthritis of the Hand... USEC (USU), down 29% after implementing financial restructuring plan under Chapter 11... Yongye (YONG), down 13% after announcing going private proposal not approved by stockholders...Nielsen (NLSN), down 2% after 30M share spot secondary offering of stock priced at $46.45.
News For SWHC;XOMA;USU;NAVB;YONG;THRM;VEEV;CSIQ;NLSN;AVAV;IMRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:56 EDTNLSNNielsen sees FY16 adjusted EPS $2.83-$2.93, consensus $2.87
Sees FY16 revenue up 4%-6%. Guidance provided in Q4 earnings presentation slides.
07:17 EDTNLSNNielsen reports Q4 Buy segment revenue down 3.2% to $879M
Reports Q4 Watch segment revenue up 2.8% to $745M.
07:17 EDTNLSNNielsen reports Q4 adjusted EPS 82c, consensus 80c
Subscribe for More Information
07:16 EDTNLSNNielsen looks forward in 2016 'with confidence'
Subscribe for More Information
07:07 EDTNAVBNavidea enrolls first patient in Lymphoseek cervical cancer study
Navidea Biopharmaceuticals announced that the first patient has been enrolled in a clinical study evaluating Lymphoseek injection in women with known cervical cancer. The study, funded by a Fast-track grant from the National Institutes of Health, National Cancer Institute will assess the use of Lymphoseek in sentinel lymph node biopsy during cervical cancer surgery in support of the existing Lymphoseek label in lymphatic mapping. Lymphoseek is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. Enrollment is currently planned in up to six sites throughout the U.S. The first patient has been enrolled by the principal investigator, Michael M. Frumovitz, M.D., M.P.H., Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, at The University of Texas MD Anderson Cancer Center. This multi-center, prospective, open-label study is designed to evaluate Lymphoseek(R) in patients with known cancer of the cervix. The trial intends to enroll up to 40 women with International Federation of Gynecology and Obstetrics IA2-IIA1 staging. Subjects will receive a single dose of Tc99m tilmanocept administered peritumorally approximately 1-2 hours before surgery. The results will report per-patient false negative rates and compare the pathology status of Lymphoseek-identified sentinel lymph nodes relative to the pathology status of non-sentinel lymph nodes in nodal staging of patients. Additionally, the study will report sensitivity, negative predictive value, and accuracy. Concordance and reverse concordance of identified nodes will be reported for the cases that use both Lymphoseek and a dye.
February 10, 2016
12:02 EDTNLSNNielsen, Hearst Television renew relationship with multi-year agreement
Subscribe for More Information
February 9, 2016
19:18 EDTCSIQOn The Fly: After Hours Movers
UP AFTER EARNINGS: Limelight Networks (LLNW), up 20%... Akamai Technologies (AKAM), up 15.7%... Marketo (MKTO), up 9.9%... Paycom Software (PAYC), up 13.8%... A10 Networks (ATEN), up 7.3%... Prospect Capital (PSEC), up 8.6%... Nuance Communications (NUAN), up 6.5%... Panera Bread (PNRA), up 2.8%. ALSO HIGHER: Empire District Electric (EDE), up 14.8% after Algonquin Power will acquire the company for $34.00 per share. DOWN AFTER EARNINGS: SolarCity (SCTY), down 32.6%... LeapFrog (LF), down 2%... Orion Energy Systems (OESX), down 23.8%... Seattle Genetics (SGEN), down 3.6%... Sangamo Biosciences (SGMO), down 7.1%... Disney (DIS), down 3.4%... Demandware (DWRE), down 2.6%. ALSO LOWER: Sunrun (RUN) is down 6.9%, Solaredge Technologies (SEDG) is down 6.6%, SunEdison (SUNE) is down 5.9%, Canadian Solar (CSIQ) is down 2.9%, SunPower (SPWR) is down 2.9%, and Tesla (TSLA) is down 2.2% following SolarCity's fourth quarter results.
17:53 EDTCSIQSolar stocks drop after SolarCity reports Q4 results
Solar stocks followed SolarCity (SCTY) down after the company reported its fourth quarter results and gave guidance for the first quarter and fiscal 2016. WHAT'S NEW: SolarCity reported Q4 earnings per share of ($2.37) against analyst expectations of ($2.59), and Q4 revenue of $115M, against consensus estimates of $105.62M. The company reported Q4 installations up 54% to 272 mega watts. Q4 commercial installations were up 82% to 51 MW while residential installations were up 49% to 221 MW. Operating Lease and Solar Energy Incentive revenue was up 53% to $75M in Q4. SolarCity sees Q1 adjusted EPS ($2.65)-($2.55), against analyst expectations of ($2.36). The company sees Q1 installations up 18% year-over-year to 180 MW. This represents a higher-than-usual seasonal slowdown due to decision to end Nevada operations and renewed focus on cash conversion cycle, particularly in longer lead-time commercial projects. The company also continues to target 1.25 gigawatts installed in FY16. The company noted that the ITC extension provides growth tailwinds. WHAT'S NOTABLE: In the earnings press release, management noted, "We closed out a strong 2015 with installations growing 73% to a record 870 MW and costs falling to new lows, though we fell short of our installation goals more than once. We are not happy with these results, and recognize our need to revamp our guidance methodology to avoid any potential shortfalls going forward. Notably, residential has consistently performed above our expectations over the last year, and we missed guidance largely on commercial installations. While we had expected the introduction in mid-2015 of a new guidance methodology that incorporated only commercial projects that were already under construction to minimize risk, clearly this wasn't sufficient. With larger projects, particularly ground-mount, this methodology still leaves sufficient time for delays to push construction past deadlines. Going forward, we plan on removing from guidance any large projects with construction deadlines late in the quarter." PRICE ACTION: Shares of SolarCity plunged 32.5% in after-hours trading to $17.79. OTHERS TO WATCH: Sunrun (RUN) is down 7%, Solaredge Technologies (SEDG) is down 8.2%, SunEdison (SUNE) is down 5.9%, Canadian Solar (CSIQ) is down 4.3%, SunPower (SPWR) is down 5.9% following SolarCity's Q4 results. Elon Musk's other publicly traded company, Tesla (TSLA), is also down after-hours by 3.1%.
09:52 EDTCSIQCanadian Solar energizes three solar power plants in Japan
Subscribe for More Information
February 8, 2016
13:03 EDTNLSNMedia General signs long-term renewal agreement for Nielsen services
Subscribe for More Information
07:05 EDTCSIQCanadian Solar begins commercial operation of three PV power plants in Japan
Canadian Solar announced that it started the commercial operation of three solar photovoltaic power plants in Japan, totaling approximately 6.2 MWp. The 6.2 MWp portfolio of projects include the 2.3 MWp Ashikita Solar Power Plant in Kumamoto City, Kumamoto Prefecture, the 2.2 MWp Minamishimabara Power Plant - East and the 1.7MWp Minamishimabara Plant - West in Minamishimabara City, Nagasaki Prefecture. The 2.3 MWp Ashikita Solar Power Plant, powered by 9,030 Canadian Solar CS6P-260P modules, achieved commercial operation on December 11, 2015. The 2.2 MWp Minamishimabara Power Plant - East, powered by 8,602 Canadian Solar CS6P-260P modules, achieved commercial operation on December 25, 2015. And finally the 1.7 MWp Minamishimabara Plant - West, powered by 6,509 Canadian Solar CS6P-260P modules, achieved commercial operation on January 29, 2016.
February 2, 2016
17:18 EDTNAVBNavidea provides update on Lymphoseek, Immunodiagnostics pipleline
Subscribe for More Information
09:14 EDTAVAVAeroVironment, NOAA to provide U.S. Coast Guard with unmanned aircraft system
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use